SKLB-163 is an anticancer agent. It acts by downregulating RhoGDI, activating JNK-1 signaling pathway and caspase-3, and reducing phosphorylated Akt and p44/42 MAPK. References: He J, Cai L, Chen Y, He Y, Wang M, Tang J, Guan H, Wang J, Peng X. Antitumor and radiosensitizing effects of SKLB-163, a novel benzothiazole-2-thiol derivative, on nasopharyngeal carcinoma by affecting the RhoGDI/JNK-1 signaling pathway. Radiother Oncol. 2018 Mar 5. pii: S0167-8140(18)30063-X. doi: 10.1016/j.radonc.2018.02.007. [Epub ahead of print] PubMed PMID: 29519627.

纯度：≥98%

CAS：1255099-06-9